Name: NRX-0492 **Cat#:** EX-A7960

Chemical Structure:



Chemical Name	3-((4-(1-(((3S)-1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)pyrrolidin-3-yl)methyl)piperidin-4-yl)phenyl)amino)-5-((R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl)pyrazine-2-carboxamide

Molecular Weight	817.9351	Storage	3 years -20°C powder 6 months -80°C in solvent Away from moisture
Formula	C43H51N11O6		
CAS No.	2416130-57-7	Synonyms	NRX 0492; NRX0492

Solubility (25°C) *	In vitro	DMSO	Soluble in DMSO
		Ethanol	N/A
		Water	N/A
	In vivo (should be freshly prepared each time)		

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual

solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions:

Mass / Volume / Concentration	1 mg	5 mg	10 mg
1 mM	1.2226 mL	6.1129 mL	12.2258 mL
5 mM	0. 2445 mL	1.2226 mL	2.4452 mL
10 mM	0. 1223 mL	0. 6113 mL	1.2226 mL

DMSO : *The above data is based on the product molecular weight 817.94.

Biological Activities:

Description	NRX-0492 is an orally active and potent degrader of BTK. NRX-0492 catalyzes ubiquitylation and proteasomal degradation of BTK with DC50≤0.2 nM and DC90≤0.5 nM, respectively. NRX-0492 inhibits B-cell receptor (BCR)-mediated signaling, transcriptional programs, and chemokine secretion. Moreover, NRX-0492 also links a noncovalent BTK-binding domain to Cereblon.[1].

References	[1]. Zhang D, et al. NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts. Blood. 2023 Mar 30;141(13):1584-1596.